Investigational drug · Phase 3
Rondecabtagene autoleucel
Also called: LYL314
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Rondecabtagene autoleucel"
First trial start
2023
May 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rondecabtagene autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
- Lymphoma, B-Cell
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Diffuse Large B Cell Lymphoma (DLBCL)
- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B Cell Lymphoma Relapsed
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Rondecabtagene autoleucel" as an intervention, largest first.
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPivotal-lookingRecruiting
Lyell Immunopharma, Inc.Industry
NCT07188558 · 400 participants (planned) · Start Jan 12, 2026 · Primary completion Dec 2029
Drug: rondecabtagene autoleucel; axicabtagene ciloleucel and 1 more · For: Large B-cell Lymphoma; Lymphoma, B-Cell; Relapsed Non-Hodgkin Lymphoma and 6 more
Sites: Gilbert, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 44 sites in all
Lyell Immunopharma, Inc.Industry
NCT05826535 · 270 participants (planned) · Start May 9, 2023 · Primary completion Dec 31, 2028
Drug: Rondecabtagene autoleucel (ronde-cel); Fludarabine and 1 more · For: Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma and 1 more
Sites: Irvine, California; Los Angeles, California; San Diego, California · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.